

1 **Antibiotic Utilisation Patterns in Tanzania: A Retrospective Longitudinal Study**
2 **Comparing Pre- and Post-COVID-19 Pandemic Using Tanzania Medicines and Medical**
3 **Devices Authority Data**

4 **Raphael Z. Sangeda¹, Sahani M. William¹, Faustine Cassian Masatu², Adonis Bitegeko²,**
5 **Yonah Hebron Mwalwisi², Emmanuel Alphonse Nkiligi², Pius Gerald Horumpende^{3,4,5},**
6 **Adam M. Fimbo²**

7 ¹Department of Pharmaceutical Microbiology, Muhimbili University of Health and Allied
8 Sciences, PO Box 65013, Dar es Salaam, Tanzania

9 ²Tanzania Medicines and Medical Devices Authority, PO Box 1253, Dodoma, Tanzania

10 ³Department of Curative Services, Ministry of Health, P.O. Box 743 Dodoma, Tanzania.
11 College, Moshi, Tanzania

12 ⁴Kilimanjaro Clinical Research Institute (KCRI), Moshi, Tanzania

13 ⁵Lugalo Infectious Diseases Research Centre, General Military Hospital (GMH) and Military
14 College of Medical Sciences (MCMS), P.O. Box 4000 Dar es Salaam, Tanzania

15

16 *Correspondence to Raphael Zozimus Sangeda email: sangeda@gmail.com

17

18 **Short title: Influence of COVID-19 on Antibiotic Utilization Patterns in Tanzania**

19 **Synopsis**

20 Background: Antimicrobial resistance (AMR) is a growing public health concern globally, and
21 misuse of antibiotics is a major contributor.

22 Objective: This study investigated antibiotic utilisation patterns before and after the COVID-19
23 pandemic in Tanzania using data from the Tanzania Medicines and Medical Devices Authority
24 (TMDA).

25 Methods: This retrospective longitudinal study analysed secondary data. The study compared
26 antibiotics consumption in defined daily doses (DDD) per 1000 inhabitants per day (DID) in two
27 distinct eras: 2018-2019 as the pre-COVID-19 era and 2020-2021 as the post-COVID-19 era.
28 Data was reorganised using Microsoft Power BI, and statistical analysis was conducted using
29 SPSS software.

30 Results: The study analysed 10,614 records and found an overall increase in antibiotics
31 consumption from 2018 to 2021. When we divided the consumption of antibiotics into a pre- and
32 post-COVID time period, with the pre-COVID period being 2018 and 2019 and the post-COVID
33 period being 2020 and 2021, we found that the consumption was 61.24 DID in the post-COVID
34 era and 50.32 DID in the pre-COVID era. Levofloxacin had the highest percentage increase in
35 use, with a 700% increase in DID after the pandemic. Azithromycin had a 163.79% increase,
36 while cefotaxime had a 600% increase. In contrast, some antibiotics exhibited a decrease in
37 usage after the pandemic, such as nalidixic acid, which had a 100% decrease, and cefpodoxime,
38 66.67% decrease.

39 Conclusion: The increase in antibiotic consumption during the COVID-19 pandemic highlights
40 the importance of implementing effective antimicrobial stewardship strategies to prevent AMR,
41 especially during pandemics.

42

43 **Introduction**

44 Antimicrobial resistance (AMR) poses a serious global health threat by hindering the treatment
45 of bacterial infections.¹ In low and middle-income countries (LMICs), Tanzania included, the
46 misuse and overuse of antibiotics have resulted in high rates of AMR, making it challenging to

47 treat bacterial infections^{2,3}. Proper regulation and minimal consumption of antibiotics are crucial
48 in reducing the prevalence of AMR in LMICs².

49 To increase healthcare professionals' capacity for health safety and security and provide
50 awareness on the appropriate use of antibiotics to reduce the development of AMR, global
51 partnerships such as the Global Health Security Agenda (GHSA) and Antimicrobial Stewardship
52 Programs (ASP) have been created. However, the COVID-19 pandemic has led to increased use
53 of antibiotics due to the absence of antiviral therapies, which may contribute to further
54 development of AMR. The second reason for increased antibiotics use has been the lack of
55 proper infection prevention control (IPC) measures in public areas and hospitals.⁴

56 The government of Tanzania has implemented various programs to provide affordable healthcare
57 services to the population, including a pre-payment system and health insurance scheme. Further,
58 the Parliament of Tanzania has recently passed a bill for universal health insurance, awaiting the
59 President's signature into law. However, achieving universal health coverage in Tanzania
60 remains challenging as many citizens still lack access to proper healthcare services and have
61 access to antibiotics without a prescription.⁵

62 The World Health Organization (WHO) has promulgated several guidelines for countries
63 embarking on AMS to optimise antibiotics prescription and dispensing. One such guideline is
64 using the AWaRe (Access, Watch, Reserve) classification of antibiotics in reporting AMU
65 data.⁶ According to this AWaRe classification, the Access group consists of antibiotics with
66 activity against a wide range of commonly encountered susceptible bacteria with lower
67 resistance potential than antibiotics in the other groups. The Watch class consists of antibiotics
68 with higher resistance potential and includes most of the highest priority agents among the
69 critically important antimicrobials for human use. The Reserve group includes antibiotics and

70 antibiotic classes that should be reserved to treat confirmed or suspected infections due to multi-
71 drug-resistant organisms. Reserve group antibiotics should be treated as "last resort" options.^{7,8}
72 This classification emphasises using the reserve group sparingly to preserve strong antibiotics for
73 serious infections. Other guidelines include the Anatomical Therapeutic Chemical (ATC)
74 classification system and the daily defined dose (DDD) system to allow for international
75 standardisation in AMU studies and permit comparison across geographical regions.⁹

76 At the onset of the COVID-19 outbreak in Tanzania in March 2020^{10,11} clinicians began
77 administering antibiotics to patients presenting with clinical signs such as cough, fever, and
78 radiological infiltrate indicative of bacterial community-acquired pneumonia. The absence of
79 antiviral therapies with proven efficacy also contributed to the widespread and excessive
80 prescription of antibiotics, leading to increased antimicrobial resistance during the pandemic¹¹⁻¹³.

81 Implementing proper antibiotic stewardship programs and increasing awareness of the
82 appropriate use of antibiotics among healthcare professionals and the general public is pivotal in
83 combating AMR. Collaboration among stakeholders is necessary to ensure effective treatment of
84 bacterial infections to combat AMR.¹⁴

85 In Tanzania, AMS efforts underpinned in the National Action Plan (NAP) were launched^{15,16} in
86 2017 and the second version¹⁷ in 2022 to help combat AMR. In 2020, the emergence of the
87 COVID-19 pandemic impacted many aspects of life, including antimicrobial use (AMU) in
88 Tanzania and globally. However, there is a paucity of AMU data in Tanzania comparing pre and
89 post-COVID-19 eras to guide AMS. The Tanzania Medicines and Medical Devices Authority
90 (TMDA) regulates the use of antibiotics in the country and collects data on their utilization¹⁵.
91 TMDA's data on antibiotics utilisation can provide valuable information to develop effective
92 strategies to combat AMR in Tanzania. Therefore, this study aimed to investigate the change in

93 antibiotic utilisation patterns before and after the COVID-19 pandemic in Tanzania, using
94 TMDA data from 2018 to 2021 to determine the trends of use before and during the COVID-19
95 pandemic outbreak in Tanzania.

96 **Methods**

97 **Study design**

98 This retrospective and longitudinal study used data from the Tanzania Medicines and Medical
99 Devices Authority (TMDA), covering four years from 2018 to 2021.

100 **Study area**

101 The study was conducted in Tanzania Mainland, and the data were collected from TMDA
102 headquarters in Dodoma. The TMDA compiled all importation data at different ports of entry
103 from January 2018 to December 2021, which were included in this study.

104 **Inclusion criteria**

105 The study included all records of antibiotics for intended human use administered systemically.

106 **Exclusion criteria**

107 Antifungals, antivirals, antiparasitic and topical antibiotics and non-antibiotics were excluded
108 from the study.

109 **Data collection**

110 Data were obtained from the TMDA headquarters in Dodoma, where individual importation data
111 were recorded from January 2018 to December 2021. The data collected include product
112 descriptions, generic and trade names, strengths, dosage forms, pack sizes, price, quantities, unit
113 prices, import permits identification, issue dates, supplier names, countries, and local importers.

114 The TMDA is the National Medicines Regulatory Authority (NMRA) responsible for regulating
115 the importation of medicines into the Tanzanian mainland market. The TMDA has developed
116 and issued regulations and procedures that compel importers to apply for an importation permit.
117 Importers' applications are evaluated, and import permits are issued and archived in the
118 Regulatory Information Management System (RIMS), from which the records of imported
119 medicines can be retrieved ¹⁵. The data included antibiotic generic name, country of origin, ATC
120 class, imports, and WHO AWaRe classification status of antibiotics received. The WHO ATC
121 classification system categorised antibiotics into their respective classes.

122 Results were expressed using the Daily Defined Doses (DDD) measurement units. Utilisation
123 was expressed in DDD per 1000 inhabitants per day (DID) in accordance with the ATC/DDD
124 WHO collaborating Center for Statistics Methodology ¹⁸.

125 **Data analysis**

126 Data collected were checked for completeness, accuracy, and omissions using Microsoft Power
127 BI. Homogeneous data were clustered and coded for easy analysis, and the findings were
128 presented in tables and graphs. Statistical analysis such as paired samples t-test was conducted in
129 Statistical Package for the Social Sciences (SPSS) version 26.0 to assess the impact of the pre-
130 and post-COVID-19 pandemic on antibiotics consumption in Tanzania. Time series and
131 regression analyses were performed to predict the annual trend of antibiotic utilisation. An
132 autoregressive integrated moving average (ARIMA, 0, 1, 0) model was established to predict the
133 trends of antibiotic use. A *p*-value of less than 0.05 was considered statistically significant.

134 **Ethical considerations**

135 Ethical clearance was obtained from the Directorate of Research and Publications of the
136 Muhimbili University of Health and Allied Sciences (MUHAS) with reference number DA.
137 25/111/28/01/2021. The TMDA granted permission to collect and use its accrued data. Data
138 privacy and confidentiality were observed throughout the study. Patient identifying information
139 was not collected since this did not involve direct patient contact; instead, secondary data from
140 the TMDA importation records was used.

141 **Results**

142 A total of 10,627 records were retrieved from the TMDA information management system. Of
143 these, 9,610 were antibiotics imported for systemic use in humans between 2018 and 2021. A
144 total of 1,017 records were excluded because they referred to antibiotics for either topical or
145 veterinary use, as they were non-J (01) level 2 ATC class and 2022 imports. A total of 117.02
146 DID was utilised in Tanzania between 2018 and 2021 (Table 1), with a mean (standard
147 deviation) of 29.25 (± 4.63) DIDs.

148 **Table 1: Annual distribution of DIDs and number of permits of antibiotics imported in**
149 **Tanzania between 2018 and 2021**

Year	DID	Number of Permits
2018	30.39831	2,491
2019	22.53625	2,426
2020	30.96806	2,152
2021	33.11989	2,541
Total	117.0225	9,610

150 Key: DID: Daily Defined Dose per 1000 inhabitants per day

151 The year 2021 had the highest DID at 33.1, 47.0% higher than 2019, with the lowest DID at
152 22.5. The consumption in 2021 accounted for 28.30% of DIDs. Annual cumulative DID started
153 shooting up in 2020, where cumulative yearly DID reached 83.9 of the total 117.02 for the four
154 years.

155 Tanzania imports these antibiotics from across continents and Kenya, India, and China were the
156 major sources of antibiotics in the pre- and post-COVID-19 eras. Tanzania and South Africa
157 were sources of antibiotics only during the pandemic era (Figure 1).



158

159 **Figure 1: Worldwide country frequency of importations pre-and post-COVID-19**
160 **pandemic. The size of the bubble signifies the frequency contributed by the respective**
161 **country.**

162 The oral and parenteral dosage forms contributed 151.18 (96.93%) and 3.33 (3.075%) of the
163 DID, respectively (Figure 2). The contribution of individual dosage forms indicates that
164 capsules contributed the most (Supplementary Figure 1) and Supplementary Table 1.

165

166


167

168

169

170

171



172 **Figure 2: DID contribution for oral (Panel A) and parenteral (panel B) antibiotics**

173 Overall, the Access group had the highest DDI at 82.9, followed by Watch, other, and Reserve.

174 Access group accounted for 70.8% (Figure 3) of DDI, while the WHO suggests > 60%. The

175 increase in the Watch group of antibiotics parallels a general decline in the Access group (Figure

176 3) and (Supplementary Figure 2).

177

178

179

180

181

182

183


184

185

186


187

188



C

D



Overall (2018-2021)

189 **Figure 3: DID contribution per WHO AWaRe classification of antibiotics consumption from**
190 **2018-2021 (Panel A-D) and overall for four years (panel E)**

191
192 The consumption of antibiotics was typically dominated by the Watch class (Supplementary
193 Figure 2).

194 Using a paired samples t-test, the mean (M) and standard deviation (SD) of antibiotics
195 consumption in the pre-COVID period (M = 1.018, SD = 3.311) was significantly different from
196 the post-COVID period (M = 1.232, SD = 3.796), $t(51) = -2.513$, $p\text{-value} = 0.015$ and paired
197 sample correlation of 0.994 with effect size, as measured by Cohen's d , being 0.312.

198 Overall, there was a 21% increase in the utilisation of antibiotics post-COVID-19. Azithromycin
199 (J01FA10) increased by 163% during the pandemic (Table 2) and Supplementary Table 2.


200 **Table 2: Percentage changes in consumption during COVID-19 for top 20 consumed**
201 **antibiotics aggregated per level 5 WHO ATC classification in DID**

DID

Antibiotic (ATC Classification level 5)	Pre-COVID	Post-COVID	Total	% change
Sulfamethoxazole + Trimethoprim (J01EE01)	21.90206	24.134214	46.036274	10.2
Amoxicillin (J01CA04)	8.958047	12.109729	21.067776	35.2
Ampicillin + Cloxacillin (J01CR50)	4.957764	6.056899	11.014663	22.2
Ciprofloxacin (J01MA02)	3.320329	3.875245	7.195574	16.7
Metronidazole (J01XD01)	2.550591	3.007772	5.558363	17.9
Azithromycin (J01FA10)	1.163502	3.063967	4.227469	163.3
Phenoxyethyl Penicillin (J01CE02)	1.839013	2.112984	3.951997	14.9
Erythromycin (J01FA01)	1.103971	1.837235	2.941206	66.4
Tinidazole (J01XD02)	0.988315	1.399698	2.388013	41.6
Amoxicillin + Clavulanate (J01CR02)	0.81814	1.280495	2.098635	56.5
Ceftriaxone (J01DD04)	0.912814	1.147269	2.060083	25.7
Cefalexin (J01DB01)	0.956694	0.637602	1.594296	-33.4
Norfloxacin (J01MA06)	0.929865	0.582542	1.512407	-37.4
Ampicillin (J01CA01)	0.737038	0.699213	1.436251	-5.1
Gentamycin (J01GB03)	0.184052	0.560144	0.744196	204.3
Amoxicillin + Flucloxacillin (J01CR50)	0.1963	0.216417	0.412717	10.2
Ciprofloxacin + Tinidazole (J01RA11)	0.219978	0.157204	0.377182	-28.5
Nitrofurantoin (J01XE01)	0.220675	0.152053	0.372728	-31.1
Tetracycline (J01AA07)	0.09207	0.222064	0.314134	141.2
Chloramphenicol (J01BA01)	0.210731	0.074664	0.285395	-64.6

202

203 Considering level 3 of the ATC classification, we noted that antibiotics consumption varies by
204 specific categories. Notably, beta-lactam antibacterials and penicillins (J01C) registered a
205 significant 28.32% increase in consumption. A 4.96 DID increase between post-covid and pre-
206 covid was noted for the beta-lactam antibacterials (Figure 4) and (Supplementary Table 3).




207

208 **Figure 4: Contribution of each class (level 3 ATC classification) of antibiotics utilised in**
209 **Tanzania from 2018 to 2021**

210 On the other hand, aminoglycoside antibacterials (J01G) exhibited a remarkable 186.44%
211 increase. In contrast, amphenicols (J01B) experienced a substantial decrease $-(63.79\%)$. The
212 class of macrolides, lincosamides and streptogramins (J01F) flagged a remarkable increase of
213 110.53% in consumption (Supplementary Table 3). In addition, annual trends of antibiotics at
214 class 3 of the ATC classification were observed (Supplementary Table 4). Similar trends are
215 indicated when considering level 4 ATC classification (Supplementary Table 5). It was noted
216 that the level 3 ATC class of sulfonamides and trimethoprim (J01E) comprised 20.62% of all
217 DID utilised, with the highest totals in pre- and post-COVID eras (Supplementary Table 4).

218 Overall, the consumption did not follow a linear pattern when fitting a linear curve (Figure 5A).


219 In addition, the autoregressive integrated moving average (ARIMA) (0, 1, 0) model (Figure 5B)
220 predicts a significant increase in utilisation and forecasts the trends of antibiotics up to the period
221 2027 modelled using the utilisation trend between 2018 and 2021.



231 *Figure 5: A) Linear curve estimation showing trends of total consumed antibiotics over four*
232 *years from 2018 to 2021 B) ARIMA model prediction of consumption from 2018 through*
233 *2027.*

234 The model estimates that by 2022 and 2027, the DID will reach 34.03 and 38.56 DIDs,
235 respectively.

236 The top 15 importers of these antibiotics contributed to 90.06% of all DIDs, with the Medical
237 Stores Department (MSD) leading by contributing 20.27% (Figure 6) and (Supplementary Table
238 6).




239

240 **Figure 6. Top 15 local importers of antibiotics utilised in Tanzania between 2018 and 2021.**

241

242 Regarding suppliers, the top 15 contributed 70.78% of the DID of antibiotics in Tanzania (Figure
243 7) and (Supplementary Table 7). The suppliers were from China, India and Kenya, consistent
244 with the map distribution (Figure 1).

245



246

247 *Figure 7: Top 15 foreign suppliers of antibiotics utilised in Tanzania between 2018 and 2021.*

248

249 Discussion

250 The Global Action Plan for Antimicrobial Resistance aims to address the mounting challenge of
251 increasing antimicrobial resistance (AMR) through the surveillance of antimicrobial use (AMU)
252 and the development of antimicrobial stewardship (AMS) programs. Consequently, in Tanzania,
253 AMS was introduced through the NAP on AMR¹⁶ in 2017 and the second version of NAP¹⁷
254 2023-2028 focuses on monitoring AMU in humans and animals.¹⁵

255 In this study, we observed an annual increase in the total consumption of antibiotics, reaching
256 117.02 DDI over four years. The consumption was 64.09 DDI in the post-COVID era and 52.93
257 DDI in the pre-COVID era. Nevertheless, the mean is 29.25 (± 4.01) compared to the mean of
258 22.07 (± 48.85) DID in 2010 to 2016 consumption data in Tanzania¹⁵.

259 A paired samples t-test indicated a significant difference in means 1.018 vs. = 1.232 in pre and
260 post-COVID periods, respectively, with p-value = 0.015 and paired sample correlation of 0.994.
261 This result suggests a statistically significant increase in antibiotics consumption during the
262 pandemic. The effect size, as measured by Cohen's d, was 0.312, suggesting a small but
263 practically significant increase. The high correlation between pre-COVID and post-COVID
264 consumption ($r = 0.994$) reinforces the reliability of these findings, suggesting that the COVID-
265 19 pandemic had a notable impact on antibiotics consumption in Tanzania.

266 The combined usage of all antibiotics increased by 21.1% from the pre-COVID period to the
267 post-COVID period. An increase was noted for gentamycin (J01GB03) at +204.3%, followed by
268 azithromycin (J01FA10) at +163.3% and tetracycline (J01AA07) at +141.2%. A decrease was
269 observed in chloramphenicol (J01BA01) (-64.6%), norfloxacin (J01MA06) (-37.4%), and
270 nitrofurantoin (J01XE01) (-31.1%). A % increase in azithromycin was noted in other studies in
271 LMICS and HICs.¹⁹ A study in Croatia showed that azithromycin distribution increased from
272 1.76 in 2017 to 2.01 Days of Therapy (DOTS) units/1000 inhabitant-days in 2017–2020,
273 indicating azithromycin overuse.²⁰ Other reports during the pandemic showed that azithromycin
274 consumption increased up to 3 times compared to the pre-COVID period.^{19–21}

275 Interestingly, the popularity of azithromycin emerged from reports of its antiviral activity and
276 also from early pandemic reports of screening indicating potential activity for SARS-CoV-2
277 alone or in combination with hydroxychloroquine.²² Later, several randomised clinical trials

278 (RCTs) suggested that azithromycin does not reduce hospital admissions, respiratory failure, or
279 death when compared to conventional therapy, and therefore, azithromycin should no longer be
280 used to treat COVID-19.²³⁻²⁸

281 Several studies have revealed a significant increase in resistance to azithromycin in some strains
282 of *Neisseria gonorrhoeae*.^{22,29} Antibiotic resistance against azithromycin also increased in *E.*
283 *coli*³⁰ and *Streptococcus pneumoniae*.³¹ Therefore, continued use of azithromycin should have
284 been limited to infections for which azithromycin is recommended rather than COVID-19.²²

285 Examining the consumption at level 3 of ATC classification, we noted a remarkable increase
286 during the post-COVID-19 era of beta-lactam antibacterials, which penicillins (J01C) and
287 aminoglycoside antibacterials (J01G) exhibited. At the same time, amphenicols (J01B)
288 experienced a substantial decrease up to -63.79%. The use of macrolides, lincosamides and
289 streptogramins (J01F) also increased remarkably by 110.53%. This finding underscores the
290 specific impact of the pandemic on the consumption of these antibiotics; the major contributor to
291 this increase was azithromycin.

292 The overall consumption of antibiotics increased from 52.935 DID (pre-COVID) to 64.088 DID
293 (post-COVID), with a total change of 21.07%.

294 Overall, the ATC level 3 class of sulfonamides and trimethoprim (J01E) ranked the top
295 consumed group with only 10.19% increase in consumption, suggesting continued reliance on
296 this class of antibiotics during the pandemic. This could be due to their effectiveness against
297 certain infections and wide availability, especially for HIV/AIDS patients. This is usually
298 indicated by the higher contribution of Sulfamethoxazole + Trimethoprim (J01EE01) used in the
299 HIV program.

300 For tetracycline (level 3 class J01A), there was a moderate consumption increase from 0.145 DID
301 (pre-COVID) to 0.251 DID (post-COVID), a 72.96% increase, even though this class ranked
302 lower compared to previous studies in Tanzania where the class was among the top contributors
303 of consumed antibiotics.¹⁵ It is important to note that the percentage change in usage should be
304 taken with caution since it is calculated based on a relatively small difference in values, and the
305 absolute values of DID for each antibiotic may vary significantly.

306 A recent study conducted in Cameroon during the COVID-19 pandemic revealed that antibiotics
307 were highly overused and misused, leading to increased AMR.³²

308 This study is one of the few conducted in sub-Saharan Africa to estimate antibiotics utilisation at
309 the national level. The data indicate an increase in the consumption of antibiotics during the
310 pandemic, with a mean of 29.25 DIDs utilised in Tanzania between 2018 and 2021. This average
311 was less than that studied between 2010 and 2016 in Tanzania, where the mean was 57.4 DIDs
312 over seven years. The study conducted in Tanzania from 2017 to 2019 also reported a slightly
313 higher average compared to this study.³³

314 These results highlight the importance of expanding the monitoring of AMU and implementing
315 AMS programs to address the issue of AMR, especially during global health crises such as the
316 COVID-19 pandemic. The observed changes in antibiotic consumption highlight the need for
317 continued monitoring and the development of interventions to ensure the rational use of
318 antibiotics since the increase in overall consumption may contribute to AMR. Antibiotic
319 stewardship programs must be emphasised post-COVID in the healthcare landscape.

320 The ARIMA forecasted that antibiotics consumption would increase between 2022 and 2027 to
321 reach 34.03 and 38.56 DIDs, respectively. This value is less than the value predicted with the

322 data from 2010–2016 which estimated that by 2022, the total of antibiotics consumed would
323 reach 89.60 DIDs.¹⁵ This may reflect the impact of AMS under the NAP implementation.^{16,34,35}

324 **Limitations of the study**

325 This study has some limitations. First, it relies on data from importation records of NMRA,
326 potentially subject to variability and errors, which could impact the accuracy of the results. The
327 data does not account for imported antibiotics that had expired or were re-exported to
328 neighbouring countries. These records also exclude efforts by manufacturers that produced some
329 antibiotics locally during the pandemic. Second, while it explores the association between the
330 pandemic and antibiotic consumption, it does not establish causality, as other unaccounted
331 factors may influence consumption trends. Third, the study's aggregated data may not capture
332 regional variations, which is important for understanding local healthcare practices and policies.
333 Additionally, the analysis's specific timeframe during the pandemic may not account for
334 evolving healthcare practices and AMS interventions, and the study does not delve into the
335 underlying factors driving these trends. Further research is warranted to understand the factors
336 driving these consumption trends and their potential impact on public health. Results need to be
337 interpreted with these limitations in mind.

338 **Conclusion**

339 This study highlights an increase in the consumption of antibiotics during the COVID-19
340 pandemic, indicating that the COVID-19 pandemic impacted the rise in antibiotics consumption
341 in Tanzania.

342 **Recommendations**

343 The surge in AMU post-COVID-19 calls for continuous monitoring and interventions to promote
344 rational use of antibiotics to combat AMR through AMS and ensure long-term effectiveness in
345 managing infectious diseases. In addition, more studies using data from community pharmacies
346 and hospitals are needed for a more accurate representation of patient antibiotic consumption.

347 **Availability of Data and Materials**

348 All data are included in this article.

349 **Acknowledgement**

350 We thank the Tanzania Medicines and Medical Devices Authority (TMDA) staff for providing
351 the importation data.

352 **Funding**

353 This work did not receive any specific funding.

354 **Transparency declarations**

355 None to declare

356 **Supplementary data**

357 Figures and Tables are available as Supplementary data at JAC-AMR Online.

358 **References**

- 359 1. Murray CJL, Ikuta KS, Sharara F, *et al.* Global burden of bacterial antimicrobial resistance in
360 2019: a systematic analysis. *Lancet* 2022; **399**: 629–55. Available at:
361 <https://linkinghub.elsevier.com/retrieve/pii/S0140673621027240>.
- 362 2. Otaigbe II, Elikwu CJ. Drivers of inappropriate antibiotic use in low- and middle-income

- 363 countries. *JAC-Antimicrobial Resist* 2023; **5**. Available at:
364 <https://academic.oup.com/jacamr/article/doi/10.1093/jacamr/dlad062/7187015>.
- 365 3. Browne AJ, Chipeta MG, Haines-Woodhouse G, *et al.* Global antibiotic consumption and
366 usage in humans, 2000–18: a spatial modelling study. *Lancet Planet Heal* 2021; **5**: e893–904.
367 Available at: <https://linkinghub.elsevier.com/retrieve/pii/S2542519621002801>.
- 368 4. Powell-Jackson T, King JJC, Makungu C, *et al.* Infection prevention and control compliance
369 in Tanzanian outpatient facilities: a cross-sectional study with implications for the control of
370 COVID-19. *Lancet Glob Heal* 2020; **8**: e780–9. Available at:
371 <https://linkinghub.elsevier.com/retrieve/pii/S2214109X20302229>.
- 372 5. Kigume R, Maluka S. The failure of community-based health insurance schemes in Tanzania:
373 opening the black box of the implementation process. *BMC Health Serv Res* 2021; **21**: 646.
374 Available at: <https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-021-06643-6>.
- 375 6. Zanichelli V, Sharland M, Cappello B, *et al.* The WHO AWaRe (Access, Watch, Reserve)
376 antibiotic book and prevention of antimicrobial resistance. *Bull World Health Organ* 2023; **101**:
377 290–6. Available at:
378 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042089/pdf/BLT.22.288614.pdf>.
- 379 7. WHO. 2021 AWaRe classification. Available at:
380 <https://www.who.int/publications/i/item/2021-aware-classification>. Accessed October 9, 2023.
- 381 8. WHO. The WHO AWaRe (Access, Watch, Reserve) antibiotic book. Available at:
382 <https://www.who.int/publications/i/item/9789240062382>. Accessed October 9, 2023.
- 383 9. Hamim H, Sangeda RZ, Bundala M, *et al.* Utilisation Trends of Antiviral and Antifungal

- 384 Agents for Human Systemic Use in Tanzania From 2010 to 2017 Using the World Health
385 Organization Collaborating Centre for Drug Statistics Methodology. *Front Trop Dis* 2021; **2**: 30.
386 Available at: <https://www.frontiersin.org/articles/10.3389/fitd.2021.723991/full>. Accessed
387 November 27, 2021.
- 388 10. Mugabe PA, Renkamp TM, Rybak C, *et al.* Governing COVID-19: analysing the effects of
389 policy responses on food systems in Tanzania. *Agric Food Secur* 2022; **11**: 47. Available at:
390 <https://agricultureandfoodsecurity.biomedcentral.com/articles/10.1186/s40066-022-00383-4>.
- 391 11. Tarimo CS, Wu J. The first confirmed case of COVID-19 in Tanzania: recommendations
392 based on lesson learned from China. *Trop Med Health* 2020; **48**: 25. Available at:
393 <https://tropmedhealth.biomedcentral.com/articles/10.1186/s41182-020-00214-x>.
- 394 12. Mfinanga SG, Mnyambwa NP, Minja DT, *et al.* Tanzania's position on the COVID-19
395 pandemic. *Lancet* 2021; **397**: 1542–3. Available at:
396 <https://linkinghub.elsevier.com/retrieve/pii/S0140673621006784>.
- 397 13. Mboya EA, Ndumwa HP, Amani DE, *et al.* Critical illness at the emergency department of a
398 Tanzanian national hospital in a three-year period 2019–2021. *BMC Emerg Med* 2023; **23**: 86.
399 Available at: <https://bmcemergmed.biomedcentral.com/articles/10.1186/s12873-023-00858-y>.
- 400 14. Simões AS, Maia MR, Gregório J, *et al.* Participatory implementation of an antibiotic
401 stewardship programme supported by an innovative surveillance and clinical decision-support
402 system. *J Hosp Infect* 2018; **100**: 257–64. Available at:
403 <https://linkinghub.elsevier.com/retrieve/pii/S0195670118303992>.
- 404 15. Sangeda RZ, Saburi HA, Masatu FC, *et al.* National Antibiotics Utilisation Trends for
405 Human Use in Tanzania from 2010 to 2016 Inferred from Tanzania Medicines and Medical

- 406 Devices Authority Importation Data. *Antibiotics* 2021; **10**: 1249. Available at:
407 <https://www.mdpi.com/2079-6382/10/10/1249>.
- 408 16. Sangeda RZ, Kibona J, Munishi C, *et al.* Assessment of Implementation of Antimicrobial
409 Resistance Surveillance and Antimicrobial Stewardship Programs in Tanzanian Health Facilities
410 a Year After Launch of the National Action Plan. *Front Public Heal* 2020; **8**: 454. Available at:
411 <https://www.frontiersin.org/article/10.3389/fpubh.2020.00454/full>. Accessed August 4, 2020.
- 412 17. World Health Organization. United Republic of Tanzania: Second national action plan on
413 antimicrobial resistance 2023-2028. Available at:
414 [https://www.who.int/publications/m/item/united-republic-of-tanzania-second-national-action-](https://www.who.int/publications/m/item/united-republic-of-tanzania-second-national-action-plan-on-antimicrobial-resistance)
415 [plan-on-antimicrobial-resistance](https://www.who.int/publications/m/item/united-republic-of-tanzania-second-national-action-plan-on-antimicrobial-resistance). Accessed September 20, 2023.
- 416 18. Hutchinson JM, Patrick DM, Marra F, *et al.* Measurement of Antibiotic Consumption: A
417 Practical Guide to the Use of the Anatomical Therapeutic Chemical Classification and Defined
418 Daily Dose System Methodology in Canada. *Can J Infect Dis* 2004; **15**: 29–35. Available at:
419 <http://www.hindawi.com/journals/cjidmm/2004/389092/abs/>. Accessed August 18, 2017.
- 420 19. Gouin KA, Creasy S, Beckerson M, *et al.* Trends in Prescribing of Antibiotics and Drugs
421 Investigated for Coronavirus Disease 2019 (COVID-19) Treatment in US Nursing Home
422 Residents During the COVID-19 Pandemic. *Clin Infect Dis* 2022; **74**: 74–82. Available at:
423 <https://academic.oup.com/cid/article/74/1/74/6167836>.
- 424 20. Bogdanić N, Močibob L, Vidović T, Soldo A, Begovać J. Azithromycin consumption during
425 the COVID-19 pandemic in Croatia, 2020 Karunasagar I, ed. *PLoS One* 2022; **17**: e0263437.
426 Available at: <https://dx.plos.org/10.1371/journal.pone.0263437>.
- 427 21. Stoichitoiu LE, Pinte L, Ceasovschih A, *et al.* In-Hospital Antibiotic Use for COVID-19:

- 428 Facts and Rationales Assessed through a Mixed-Methods Study. *J Clin Med* 2022; **11**: 3194.
429 Available at: <https://www.mdpi.com/2077-0383/11/11/3194>.
- 430 22. Kournoutou GG, Dinos G. Azithromycin through the Lens of the COVID-19 Treatment.
431 *Antibiotics* 2022; **11**: 1063. Available at: <https://www.mdpi.com/2079-6382/11/8/1063>.
- 432 23. Oldenburg CE, Pinsky BA, Brogdon J, *et al.* Effect of Oral Azithromycin vs Placebo on
433 COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection. *JAMA* 2021; **326**: 490.
434 Available at: <https://jamanetwork.com/journals/jama/fullarticle/2782166>.
- 435 24. Butler CC, Dorward J, Yu L-M, *et al.* Azithromycin for community treatment of suspected
436 COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a
437 randomised, controlled, open-label, adaptive platform trial. *Lancet* 2021; **397**: 1063–74.
438 Available at: <https://linkinghub.elsevier.com/retrieve/pii/S014067362100461X>.
- 439 25. Hinks TSC, Barber VS, Black J, *et al.* A multi-centre open-label two-arm randomised
440 superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study
441 protocol for the ATOMIC2 trial. *Trials* 2020; **21**: 718. Available at:
442 <https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04593-8>.
- 443 26. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with
444 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet (London, England)* 2021; **397**: 1637–45. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/33933206>.
- 445
446 27. Gyselinck I, Janssens W, Verhamme P, Vos R. Rationale for azithromycin in COVID-19: an
447 overview of existing evidence. *BMJ Open Respir Res* 2021; **8**: e000806. Available at:
448 <https://bmjopenrespres.bmj.com/lookup/doi/10.1136/bmjresp-2020-000806>.

- 449 28. Furtado RHM, Berwanger O, Fonseca HA, *et al.* Azithromycin in addition to standard of care
450 versus standard of care alone in the treatment of patients admitted to the hospital with severe
451 COVID-19 in Brazil (COALITION II): a randomised clinical trial. *Lancet* 2020; **396**: 959–67.
452 Available at: <https://linkinghub.elsevier.com/retrieve/pii/S0140673620318626>.
- 453 29. Belkacem A, Jacquier H, Goubard A, *et al.* Molecular epidemiology and mechanisms of
454 resistance of azithromycin-resistant *Neisseria gonorrhoeae* isolated in France during 2013–14. *J*
455 *Antimicrob Chemother* 2016; **71**: 2471–8. Available at: [https://academic.oup.com/jac/article-](https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dkw182)
456 [lookup/doi/10.1093/jac/dkw182](https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dkw182).
- 457 30. Gomes C, Ruiz-Roldán L, Mateu J, Ochoa TJ, Ruiz J. Azithromycin resistance levels and
458 mechanisms in *Escherichia coli*. *Sci Rep* 2019; **9**: 6089. Available at:
459 <https://www.nature.com/articles/s41598-019-42423-3>.
- 460 31. Hart JD, Samikwa L, Meleke H, *et al.* Prevalence of nasopharyngeal *Streptococcus*
461 *pneumoniae* carriage and resistance to macrolides in the setting of azithromycin mass drug
462 administration: analysis from a cluster-randomised controlled trial in Malawi, 2015–17. *The*
463 *Lancet Microbe* 2022; **3**: e142–50. Available at:
464 <https://linkinghub.elsevier.com/retrieve/pii/S2666524721002792>.
- 465 32. Djuikoue CI, Yamdeu Djonkhou W, Epie Bekolo C, *et al.* Prevalence and Antibiotic
466 Resistance Pattern of *Streptococcus*, *Staphylococcus*, *Neisseria meningitidis* and
467 *Enterobacteriaceae* in Two Reference Hospitals of Yaoundé: An Overview before and during
468 COVID-19 Pandemic Era. *Antibiotics* 2023; **12**: 929. Available at: [https://www.mdpi.com/2079-](https://www.mdpi.com/2079-6382/12/5/929)
469 [6382/12/5/929](https://www.mdpi.com/2079-6382/12/5/929).
- 470 33. Mbwasi R, Mapunjo S, Wittenauer R, *et al.* National Consumption of Antimicrobials in

471 Tanzania \square : 2017 – 2019. 2020; **11**: 2017–9.

472 34. Frumence G, Mboera LEG, Sindato C, *et al.* The Governance and Implementation of the
473 National Action Plan on Antimicrobial Resistance in Tanzania: A Qualitative Study. *Antibiotics*
474 2021; **10**: 273. Available at: <https://www.mdpi.com/2079-6382/10/3/273>.

475 35. Nkinda L, Mwakawanga DL, Kibwana UO, *et al.* Implementation of antibiotic stewardship
476 programmes in paediatric patients in regional referral hospitals in Tanzania: experience from
477 prescribers and dispensers. *JAC-Antimicrobial Resist* 2022; **4**: dlac118. Available at:
478 <http://www.ncbi.nlm.nih.gov/pubmed/36439992>.

479

480

481 **Supplementary Figures and Tables**

482 **Antibiotic Utilisation Patterns in Tanzania: A Retrospective Longitudinal Study**

483 **Comparing Pre- and Post-COVID-19 Pandemic Using Tanzania Medicines and Medical**

484 **Devices Authority Data**

485 **Raphael Z. Sangeda¹, Sahani M. William¹, Faustine Cassian Masatu², Adonis Bitegeko²,**

486 **Yonah Hebron Mwalwisi², Emmanuel Alphonse Nkiligi², Pius Gerald Horumpende^{3,4,5},**

487 **Adam M. Fimbo²**

488 ¹Department of Pharmaceutical Microbiology, Muhimbili University of Health and Allied
489 Sciences, P.O. Box 65013, Dar es Salaam, Tanzania

490 ²Tanzania Medicines and Medical Devices Authority, P.O. Box 1253, Dodoma, Tanzania

491 ³Department of Curative Services, Ministry of Health, P.O. Box 743 Dodoma, Tanzania.

492 College, Moshi, Tanzania

493 ⁴Kilimanjaro Clinical Research Institute (KCRI), Moshi, Tanzania

494 ⁵Lugalo Infectious Diseases Research Centre, General Military Hospital (GMH) and Military
495 College of Medical Sciences (MCMS), P.O. Box 4000 Dar es Salaam, Tanzania


496

497 *Correspondence to Raphael Zozimus Sangeda email: sangeda@gmail.com

498

499 **Short title: Influence of COVID-19 on Antibiotic Utilization Patterns in Tanzania**


500



501

502 **Supplementary Figure 1: Contribution of antibiotics consumption per dosage and by**
 503 **COVID-19 era**

504



505

506 **Supplementary Figure 2: Distribution of Defined Daily Dose (DDD per 1000 inhabitants per**
 507 **day (DID)) of antibiotics per the World Health Organization's AWaRe class for antibiotics**
 508 **utilised in Tanzania from 2018 to 2020.**

509

510

511

512 **Supplementary Table 1: Annual contribution of consumption of antibiotics per dosage**
 513 **form**

	Year		% contribution		
	2018	2019	2020	2021	All time
Dosage form	2018	2019	2020	2021	All time
Capsules	52.5	67.2	84.7	80.2	71.1
Injections	2.3	2.5	3.9	3.4	3.0
Pessaries				0.0	0.0
Syrup	2.7	1.6	0.7	0.9	1.5
Tablets	42.5	28.7	10.8	15.5	24.4
Total	100.0	100.0	100.0	100.0	100.0

514

515

516

517

518 **Supplementary Table 2: Percentage changes in consumption during COVID-19 for top 20**
 519 **consumed antibiotics aggregated per level 5 WHO ATC classification in DID**

Antibiotic (ATC level 5 code)	DID			% Change
	Pre COVID	Post COVID	Total	
Sulfamethoxazole + Trimethoprim (J01EE01)	21.90206	24.134214	46.036274	10.2
Amoxicillin (J01CA04)	8.958047	12.109729	21.067776	35.2
Ampicillin + Cloxacillin (J01CR50)	4.957764	6.056899	11.014663	22.2
Ciprofloxacin (J01MA02)	3.320329	3.875245	7.195574	16.7
Metronidazole (J01XD01)	2.550591	3.007772	5.558363	17.9
Azithromycin (J01FA10)	1.163502	3.063967	4.227469	163.3
Phenoxyethyl Penicillin (J01CE02)	1.839013	2.112984	3.951997	14.9
Erythromycin (J01FA01)	1.103971	1.837235	2.941206	66.4
Tinidazole (J01XD02)	0.988315	1.399698	2.388013	41.6
Amoxicillin + Clavulanate (J01CR02)	0.81814	1.280495	2.098635	56.5
Ceftriaxone (J01DD04)	0.912814	1.147269	2.060083	25.7

Cefalexin (J01DB01)	0.956694	0.637602	1.594296	-33.4
Norfloxacin (J01MA06)	0.929865	0.582542	1.512407	-37.4
Ampicillin (J01CA01)	0.737038	0.699213	1.436251	-5.1
Gentamycin (J01GB03)	0.184052	0.560144	0.744196	204.3
Amoxicillin + Flucloxacillin (J01CR50)	0.1963	0.216417	0.412717	10.2
Ciprofloxacin + Tinidazole (J01RA11)	0.219978	0.157204	0.377182	-28.5
Nitrofurantoin (J01XE01)	0.220675	0.152053	0.372728	-31.1
Tetracycline (J01AA07)	0.09207	0.222064	0.314134	141.2
Chloramphenicol (J01BA01)	0.210731	0.074664	0.285395	-64.6
Cefixime (J01DD08)	0.089679	0.18745	0.277129	109.0
Clarithromycin (J01FA09)	0.116368	0.116796	0.233164	0.4
Ornidazole (J01XD03)	0.124153	0.053845	0.177998	-56.6
Cefuroxime (J01DC02)	0.073682	0.04626	0.119942	-37.2
Ofloxacin (J01MA01)	0.052129	0.06318	0.115309	21.2
Cefadroxil (J01DB05)	0.041038	0.050992	0.09203	24.3
Levofloxacin (J01MA13)	0.008836	0.082444	0.09128	833.0
Doxycycline (J01AA02)	0.052935	0.028352	0.081287	-46.4
Cefotaxime (J01DD01)	0.005643	0.066155	0.071798	1072.3
Cefpodoxime (J01DD13)	0.02914	0.006786	0.035926	-76.7
Moxifloxacin (J01MA15)	0.015046	0.012868	0.027914	-14.5
Dexamethasone + Neomycin + Polymyxin B (J01GB05)	0.014225	0.008568	0.022793	-39.8
Lomefloxacin (J01MA07)	0.010553	0.008616	0.019169	-18.4
Meropenem (J01DH02)	0.00761	0.009849	0.017459	29.4
Ampicillin + enzyme inhibitor (J01CA51)	0.011029	0.004753	0.015782	-56.9
Nalidixic Acid (J01MB02)	0.008157		0.008157	-100.0
Lignocaine + Chloramphenicol + Beclomethasone Dipropiote + Clotrimazole (J01BA01)	0.003076	0.002752	0.005828	-10.5
Clindamycin (J01FF01)	0.00078	0.002762	0.003542	254.1
Spectinomycin (J01XX04)	0.001507	0.00086	0.002367	-42.9
Cefepime (J01DE01)	0.001017	0.000937	0.001954	-7.9
Flucloxacillin (J01CF05)	0.001857		0.001857	-100.0
Vancomycin (J01XA01)	0.000392	0.001189	0.001581	203.3
Cefoperazone + combinations (J01DD62)	0.000996	0.000461	0.001457	-53.7
Cefoperazone + Sulbactam (J01DD62)	0.000497	0.000615	0.001112	23.7
Bacitracin + Neomycin + Polymyxin B (J01XX10)	0.000561	0.000423	0.000984	-24.6
Cefpirome (J01DE02)		0.000867	0.000867	NA
Cilastatin + Imipenem (J01DH51)	0.0003	0.000487	0.000787	62.3
Cloxacillin (J01CF02)		0.000709	0.000709	NA
Amikacin (J01GB06)	0.00027	0.000181	0.000451	-33.0
Cefazolin (J01DB04)	0.000174	0.000275	0.000449	58.0

Tylosin Tartrate + Doxycycline Hyclate (J01AA02)		0.000389	0.000389	NA
PolyMyxin B (J01XB02)	0.000199	0.0001	0.000299	-49.7
Neomycin (J01GB05)		0.000267	0.000267	NA
Roxithromycin (J01FA06)	0.000199		0.000199	-100.0
Sulfadiazine + Trimethoprim (J01EE02)	0.000051	0.000136	0.000187	166.7
Kanamycin (J01GB04)	0.000153		0.000153	-100.0
Sulfadimidine (J01EB03)		0.000123	0.000123	NA
Trimethoprim (J01EA01)	0.00007	0.000035	0.000105	-50.0
Cefaclor (J01DC04)	0.000077	0.000027	0.000104	-64.9
Imipenem + enzyme inhibitor (J01DH56)	0.000089		0.000089	-100.0
Ceftazidime (J01DD02)	0.000056	0.000024	0.00008	-57.1
Linezolid (J01XX08)	0.00007		0.00007	-100.0
Tobramycin (J01GB01)	0.000001	0.000002	0.000003	100.0
Isoniazid + Pyridoxine + Sulfamethoxazole + Trimethoprim (J04AM08)		0.000001	0.000001	NA
Ampicillin + Sulbactam (J01CR01)	0		0	NA
Azithromycin + fluconazole + secnidazole (J01RA07)		0	0	NA
Erythromycin + combinations (J01FA01)		0	0	N.A.
Period Total	52.934564	64.087946	117.02251	21.1

520

521

522 **Supplementary Table 3: Consumption aggregated at ATC level 3 in the pre-COVID-19 and**
 523 **post-COVID-19 era in Tanzania**

ATC level 3 Description (Code)	Pre COVID	Post COVID	Class Total	Change %
Sulfonamides And Trimethoprim (J01E)	21.902181	24.134508	46.036689	10.19226
Beta-Lactam Antibacterials, Penicillins (J01C)	17.519188	22.481199	40.000387	28.32329
Quinolone Antibacterials (J01M)	4.344915	4.624895	8.96981	6.443854
Other Antibacterials (J01X)	3.886463	4.615939	8.502402	18.76966
Macrolides, Lincosamides And Streptogramins (J01F)	2.38482	5.02076	7.40558	110.5299
Other Beta-Lactam Antibacterials (J01D)	2.119506	2.156056	4.275562	1.724458
Aminoglycoside Antibacterials (J01G)	0.198701	0.569163	0.767864	186.4419
Tetracyclines (J01A)	0.145005	0.250806	0.395811	72.96369
Combinations Of Antibacterials (J01R)	0.219978	0.157205	0.377183	-28.536
Amphenicols (J01B)	0.213806	0.077416	0.291222	-63.7915
Period Total	52.934563	64.087947	117.02251	21.07014

524

525

526 **Supplementary Table 4: Consumption aggregated at ATC level 3 from 2018 to 2021 in**
 527 **Tanzania**

ATC Class level 3	2018	2019	2020	2021	Four Years Total
Sulfonamides And Trimethoprim (J01E)	14.617083	7.285097	12.50324	11.631268	46.036688
Beta-Lactam Antibacterials, Penicillins (J01C)	10.173568	7.34562	11.12656	11.35464	40.000388
Quinolone Antibacterials (J01M)	1.462383	2.882532	2.309063	2.315832	8.96981
Other Antibacterials (J01X)	1.784649	2.101814	1.960377	2.655562	8.502402
Macrolides, Lincosamides And Streptogramins (J01F)	1.064215	1.320605	1.65612	3.364641	7.405581
Other Beta-Lactam Antibacterials (J01D)	0.872695	1.24681	1.157145	0.998911	4.275561
Aminoglycoside Antibacterials (J01G)	0.155795	0.042906	0.07892	0.490243	0.767864
Tetracyclines (J01A)	0.042675	0.10233	0.10106	0.149746	0.395811
Combinations Of Antibacterials (J01R)	0.060057	0.159921	0.024369	0.132836	0.377183
Amphenicols (J01B)	0.165188	0.048619	0.051204	0.026212	0.291223
Drugs For Treatment Of Tuberculosis (J04A)				0.000001	0.000001
Year Total	30.398308	22.536254	30.968058	33.119892	117.022512

528

529

530 **Supplementary Table 5: Consumption aggregated at ATC level 4 from 2018 to 2021 in**
 531 **Tanzania.**

ATC Class level 4	2018	2019	2020	2021	Four years Total
Amphenicols (J01BA)	0.165188	0.048619	0.051204	0.026212	0.291223
Beta-Lactamase Resistant Penicillins (J01CF)	0.000632	0.001225	0.000709		0.002566
Beta-Lactamase Sensitive Penicillins (J01CE)	0.97563	0.863383	1.066293	1.04669	3.951996
Carbapenems (J01DH)	0.006551	0.001447	0.00222	0.008116	0.018334

Combinations Of Antibacterials (J01RA)	0.060057	0.159921	0.024369	0.132836	0.377183
Combinations Of Drugs For Treatment Of Tuberculosis (J04AM)				0.000001	0.000001
Combinations Of Penicillins, Incl. Beta-Lactamase Inhibitors (J01CR)	3.626861	2.345343	3.431805	4.122006	13.526015
Combinations Of Sulphonamides And Trimethoprim Incl. Derivatives (J01EE)	14.617026	7.285085	12.503105	11.631245	46.036461
First Generation Cephalosporins (J01DB)	0.310298	0.687607	0.376731	0.312137	1.686773
Fluoroquinolones (J01MA)	1.454226	2.882532	2.309063	2.315832	8.961653
Fourth Generation Cephalosporins (J01DE)	0.000656	0.000361	0.00063	0.001174	0.002821
Glycopeptide Antibacterials (J01XA)	0.000293	0.000098	0.000166	0.001022	0.001579
Imidazole Derivatives (J01XD)	1.710669	1.952389	1.893326	2.567989	8.124373
Lincosamides (J01FF)	0.000276	0.000503	0.000896	0.001866	0.003541
Macrolides (J01FA)	1.063939	1.320101	1.655224	3.362775	7.402039
Other Aminoglycosides (J01GB)	0.155795	0.042906	0.07892	0.490243	0.767864
Other Antibacterials (J01XX)	0.001017	0.001122	0	0.001283	0.003422
Other Quinolones (J01MB)	0.008157				0.008157
Penicillins With Extended Spectrum (J01CA)	5.570445	4.135668	6.627752	6.185944	22.519809
Second Generation Cephalosporins (J01DC)	0.042137	0.031622	0.009737	0.03655	0.120046
Short-Acting Sulfonamides (J01EB)			0.000123		0.000123
Tetracyclines (J01AA)	0.042675	0.10233	0.10106	0.149746	0.395811
Third Generation Cephalosporins (J01DD)	0.513052	0.525773	0.767827	0.640932	2.447584
(Not classified)	0.072727	0.148216	0.066897	0.085291	0.373131
Year Total	30.398307	22.536251	30.968057	33.11989	117.022505

532

533 **Supplementary Table 6: Top (local) importers of antibiotics utilised in Tanzania between**
 534 **2018 and 2021, with the proportion of each importer in DID in four years and the cumulative**
 535 **contribution for each local importer.**

Importer	2018	2019	2020	2021	Total	Proportion	Cumulative % contribution
Medical Stores Department	12.832301	4.068537	2.884632	3.929656	23.715126	20.26544022	20.2654402
Importer 2	3.61511	3.910759	8.653665	5.725965	21.905499	18.71904794	38.9844882
Importer 3	3.08651	2.834042	5.760543	3.326914	15.008009	12.82489114	51.8093793
Importer 4	1.490486	2.196296	2.374687	3.217808	9.279277	7.929480676	59.73886
Importer 5			0.880014	5.746847	6.626861	5.662894452	65.4017544
Importer 6	1.105711	0.629544	1.501565	1.104843	4.341663	3.710109404	69.1118638
Importer 7	2.82273	0.603366	0.374427	0.270447	4.07097	3.478792362	72.5906562
Importer 8		1.462745	1.136031	1.264955	3.863731	3.301699077	75.8923553
Importer 9	0.130747	1.015805	0.541305	1.593834	3.281691	2.804324666	78.6966799

Importer 10	0.438368	0.577306	0.945605	0.792103	2.753382	2.352865354	81.0495453
Importer 11	0.948832	0.737385	0.49991	0.553922	2.740049	2.341471819	83.3910171
Importer 12	0.357483	0.482545	0.94044	0.807016	2.587484	2.211099462	85.6021166
Importer 13	0.314455	0.718956	1.039605	0.300066	2.373082	2.027885132	87.6300017
Importer 14	0.186325	0.427968	0.267492	0.554332	1.436117	1.227214362	88.8572161
Importer 15	0.164737	0.143458	0.482578	0.611514	1.402287	1.198305393	90.0555215

536

537

538

539 **Supplementary Table 7: Top fifteen (foreign) suppliers of antibiotics utilised in Tanzania**
 540 *between 2018 and 2021, with the proportion of each supplier in DID in four years and the*
 541 *cumulative contribution for each company.*

Suppliers	2018	2019	2020	2021	Total	Proportion of total DDI (%)	Cumulative % contribution
Supplier 1, China	11.98331	3.45388	1.077391	0.292197	16.80677	14.36	14.36
Supplier 2, India	2.731248	1.581349	2.996334	1.57263	8.881561	7.59	21.95
Supplier 3, Kenya	0.193801	1.371094	0.696028	5.364539	7.625462	6.52	28.47
Supplier 4, Kenya	0.160403	3.281153	2.964335	3.578167	9.984058	8.53	37.00
Supplier 5, Kenya	0.915313	1.474415	2.85964	1.344799	6.594167	5.63	42.63
Supplier 6, India	0.185795	1.311286	1.165614	3.017761	5.680456	4.85	47.49
Supplier 7, India	0.571838	0.359887	2.322161	1.172949	4.426835	3.78	51.27
Supplier 8, India	0.358325	0.462936	1.478326	2.053054	4.352641	3.72	54.99
Supplier 9, Kenya	3.539278	0.218147	0.358759	0.063429	4.179613	3.57	58.56
Supplier 10, India	0.607576	0.62307	0.77138	1.735099	3.737125	3.19	61.76
Supplier 11, India	0.619548	0.425639	1.864228		2.909415	2.49	64.24
Supplier 12, India	0.760897	0.729129	0.559022	0.656169	2.705217	2.31	66.55
Supplier 13, India		0.83642	0.705891	1.047714	2.590025	2.21	68.77
Supplier 14, India	0.383732	0.805343	0.555065	0.608778	2.352918	2.01	70.78

542

543 **Supplementary Table 8: Predicted Defined Dose per 1000 inhabitants per day (DID) from**
544 **2022 through 2027 from autoregressive integrated moving average ARIMA (0, 1, 0) model**

Year	Actual Daily Defined Dose per 1000 inhabitants per day (DID)	Predicted DID	Lower Control Limit (LCL) of DID	Upper Control Limit (UCL) DID
2018	30.398308			
2019	22.536254	31.305503	-4.05338	66.66438
2020	30.968058	23.443449	-11.9154	58.80233
2021	33.119892	31.875253	-3.48363	67.23413
2022		34.027087	-1.33179	69.38597
2023		34.934281	-15.0707	84.93929
2024		35.841476	-25.4019	97.08485
2025		36.748671	-33.9691	107.4664
2026		37.655865	-41.409	116.7207
2027		38.56306	-48.0482	125.1743

545

546

547